Cantor Fitzgerald Predicts Pharvaris FY2026 Earnings

Pharvaris (NASDAQ:PHVS) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Pharvaris in a report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will earn ($3.75) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

Several other research firms also recently weighed in on PHVS. Wedbush reiterated an “outperform” rating and issued a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Guggenheim began coverage on shares of Pharvaris in a research report on Wednesday. They issued a “buy” rating and a $32.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.20.

Pharvaris Trading Up 1.1%

PHVS opened at $17.23 on Wednesday. Pharvaris has a 1-year low of $11.51 and a 1-year high of $25.50. The company has a market capitalization of $900.96 million, a PE ratio of -6.15 and a beta of -2.86. The firm’s 50 day simple moving average is $15.83 and its two-hundred day simple moving average is $16.95.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC raised its position in shares of Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after purchasing an additional 189,714 shares during the period. Soleus Capital Management L.P. raised its position in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock valued at $15,617,000 after purchasing an additional 216,483 shares during the period. Octagon Capital Advisors LP grew its stake in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after acquiring an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP grew its stake in Pharvaris by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after acquiring an additional 18,200 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock valued at $8,510,000 after acquiring an additional 118,408 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.